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Abstract
Background: We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18) human
papillomavirus (HPV) vaccine to the current screening programme in the UK compared to
screening alone.
Methods: A Markov model of the natural history of HPV infection incorporating screening and
vaccination was developed. A vaccine that prevents 98% of HPV 6, 11, 16 and 18-associated disease,
with a lifetime duration and 85% coverage, in conjunction with current screening was considered.
Results:  Vaccination with screening, compared to screening alone, was associated with an
incremental cost-effectiveness ratio of £21,059 per quality adjusted life year (QALY) and £34,687
per life year saved (LYS). More than 400 cases of cervical cancer, 6700 cases of cervical
intraepithelial neoplasia and 4750 cases of genital warts could be avoided per 100,000 vaccinated
girls. Results were sensitive to assumptions about the need for a booster, the duration of vaccine
efficacy and discount rate.
Conclusion: These analyses suggest that adding a quadrivalent HPV vaccine to current screening
in the UK could be a cost-effective method for further reducing the burden of cervical cancer.
Background
Despite a well-organised screening programme in the UK,
and a marked decrease in cervical cancer incidence since
1988, there were 3,181 new cervical cancer cases and
1,529 deaths reported in 2002. In 2003, the National
Health Service Cervical Screening Programme modified
its recommendations by increasing the age to begin
screening from 20 years to 25 years combined with a more
frequent screening interval (every 3 years in women aged
25 to 49 years and 5 years for women between 50 and 64).
Invasive carcinoma of the cervix is preceded by premalig-
nant lesions. These precancerous lesions are defined as
cervical intraepithelial neoplasia (CIN), and classified as
low grade (CIN 1) or high grade (CIN 2 or CIN 3) accord-
ing to severity. Prevention of cervical cancer has been
based on early detection of these precancerous lesions
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using conventional Pap smear tests or, more recently, liq-
uid-based cytology (LBC) tests. However, with the knowl-
edge that infection with oncogenic human
papillomavirus (HPV) is necessary for the development of
cervical cancer [1], alternative methods, beside the Pap
smear are being researched to improve cervical cancer pre-
vention. In 2006, the first prophylactic quadrivalent HPV
recombinant vaccine (HPV types 6,11,16,18) (Gardasil®,
Merck, Sharpe and Dohme (MSD), Whitehouse Station,
New Jersey, USA) has been granted a marketing authorisa-
tion in the European Union [2]. This vaccine is indicated
for the prevention of high grade cervical dysplasia (CIN 2/
3), cervical carcinoma, high grade vulvar dysplastic
lesions (VIN 2/3) and external genital warts causally
related to HPV types 6, 11, 16 and 18. More recently, the
European Commission has granted a marketing authori-
sation for a second cervical cancer vaccine (Cervarix, Glax-
oSmithKline Biologicals s.a., Rixensart, Belgium) that is
indicated for the prevention of precancerous cervical
lesions (high-grade cervical intraepithelial neoplasia
[CIN] grades 2 and 3) and cervical cancer causally related
to human papillomavirus (HPV) types 16 and 18 [3].
Although the UK Health Minister has recommended the
use of the HPV vaccine for girls aged 12–13 and catch-up
for girls aged up to 19 years, a decision has not yet been
made regarding which vaccine to use in the National
Immunization program [4].
The quadrivalent vaccine showed >90% efficacy in pre-
venting pre-cancerous high grade lesions due to these two
HPV types [5,6]. This vaccine presents an opportunity to
further reduce cancer incidence and mortality.
Genital warts are the most common sexually transmitted
infection in the UK. In 2004, 79,678 first attack cases of
genital warts were reported in Genitourinary Medicine
(GUM) clinics [7]. Of these, 47% were diagnosed in
women and 53% in men. Current methods for treating
warts include therapies such as cryotherapy, electrocau-
tery, podophyllotoxin and imiquimod. However, up to
40% of patients experience a recurrence of genital warts
post-treatment [8]. The psychological impact of warts can
be high; both men and women report feelings of embar-
rassment and depression [9]. Over 90% of genital warts
are attributable to infection with HPV types 6 and 11 [10].
Results from a Phase III trial of a quadrivalent vaccine that
includes HPV types 6 and 11, in addition to the oncogenic
HPV types 16 and 18, showed that vaccination prevented
>90% of warts [11].
We examined the potential effectiveness and cost-effec-
tiveness of a quadrivalent vaccine targeted at HPV types 6,
11, 16 and 18, administered to a cohort of girls aged 12
through a school-based vaccination programme in con-
junction with the current screening programme in the UK
over a lifetime period.
Methods
We adapted a previously published and validated state-
transition Markov model of HPV infection and cervical
cancer [12,13] to estimate total lifetime costs, life expect-
ancy and incremental cost-effectiveness ratios (ICERs)
associated with different screening strategies either alone
or in combination with vaccination to prevent HPV types
6, 11, 16 and 18 in the UK. Estimates and ranges used in
the model for the natural history are presented in Table 1.
Briefly, the model simulates a cohort of women at age 12
and follows them until age 85 years. Movement through
the health states of the model (i.e. HPV infection, CIN 1,
CIN 2, CIN 3, Cancer [Stages I–IV]) over time is based on
yearly transition probabilities derived from the literature.
Women who are infected with HPV can have their infec-
tion clear, progress, or persist. For those women whose
infections persist, the majority is assumed to develop CIN
1 but a minority is assumed to develop CIN 2 directly;
these rates are age-dependant. Women who develop CIN
1, CIN 2, or CIN 3 can have their disease progress, regress,
or persist. Women with cancer (stages I, II, III, IV) can
have their cancer detected during screening or if they
present to a health care provider based on symptoms.
Women who do not have their disease detected can
progress to the next stage, remain in the same stage, or die
of cervical cancer. Each year, women also face an age-spe-
cific risk of dying from other causes.
The model was calibrated to produce prevalence curves
for HPV infection [14,15], cervical cancer lifetime risks
and cervical cancer incidence in the UK [16]. The model
was revised to separate high-grade CIN into CIN 2 and
CIN 3 using data from Canfell et al. [17]. Non-cervical
cancer deaths were estimated using data from UK statistics
[18]. Benign hysterectomy rates were estimated using age-
specific estimates from Redburn et al. [19]. Cancer pro-
gression rates between FIGO (International Federation of
Gynecology and Obstetrics) stages (FIGO I through IV)
were based on the original model [12]. Cancer stage-spe-
cific symptoms were based on calibrating the model to
produce a stage-specific distribution of cancer, in the
absence of screening consistent with Bjorge et al. [20].
Five-year stage-specific survival was based on data from
the West Midlands [21]. Finally, we assumed that only
women who were normal (i.e. did not have CIN or cervi-
cal cancer) were at risk for developing warts due to a lack
of published data on women who have CIN or cancer and
warts. We used data from the Health Protection Agency
[7] to determine the "incidence" of symptomatic warts,
since these data are based on women presenting to clinics
with symptoms. We conservatively assumed that allCost Effectiveness and Resource Allocation 2008, 6:4 http://www.resource-allocation.com/content/6/1/4
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Table 1: Annual transition probabilities for the natural history model
Parameters Age Transition 
probability
Time 
period
References
Normal
Uninfected to Cervical HPV infection (HPV 
incidence)
10–12 0.0000 12 months Calibrated from Canfell et al17
13 0.0100 12 months
14 0.0300 12 months
15 0.0400 12 months
16 0.0460 12 months
17 0.0700 12 months
18 0.0700 12 months
19 0.1700 12 months
20–21 0.2000 12 months
22 0.1200 12 months
23 0.1100 12 months
24–29 0.0850 12 months
30–33 0.0320 12 months
34–49 0.0170 12 months
50+ 0.0095 12 months
HPV infected state
Progression from HPV infection to SIL – all risk HPV 0.0959 12 months Canfell et al17
Percentage CIN 2 among SIL 0.1350 12 months Calibrated based on Myers et al12 and Canfell et al17
Regression of CIN 1 to normal from HPV infection 12–24 0.7000 18 months Calibrated based on Myers et al12 and Canfell et al17
25–29 0.5000 18 months
30–39 0.4000 18 months
40–49 0.2700 18 months
50+ 0.1000 18 months
CIN 1 Canfell et al17
Progression from CIN 1 to CIN 2 – all risk HPV 16–34 0.0297 12 months
35+ 0.1485 12 months
Progression from CIN 1 to CIN 3 – all risk HPV 0.0301 12 months
Regression to HPV infected state – all risk HPV 16–34 0.2248 12 months
35+ 0.1124 12 months
Proportion regressing to normal 0.9000 12 months
CIN 2 Canfell et al17
Progression from CIN 2 to CIN 3 16–34 0.0389 12 months
35–44 0.0797 12 months
45+ 0.1062 12 months
Regression from CIN 2 to CIN 1 0.2430 12 months
Regression from CIN 2 to uninfected or HPV 
infections
0.1901 12 months
Proportion regressing directly to normal 0.9000 12 months
CIN 3 Canfell et al17
Regression CIN 3 to CIN 1 – all risk HPV 0.0000 12 months
Regression from CIN 3 to CIN 2 – all risk HPV 0.0135 12 months
CIN 3 to uninfected or HPV infection 16–44 0.0135 12 months
45+ 0.0100 12 months
Proportion CIN 3 regressing directly to uninfected 0.5000 12 months
Proportion CIN 3 progressing to FIGO I cancer 0.0127 12 months
Cervical cancer Myers et al12
FIGO 1
Progression rates 0.9000 48 months
Probability of symptoms 0.1850 12 months
FIGO 2
Progression rates 0.9000 36 months
Probability of symptoms 0.3000 12 monthsCost Effectiveness and Resource Allocation 2008, 6:4 http://www.resource-allocation.com/content/6/1/4
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women with symptomatic warts would receive treatment
and that treatment was 100% effective.
For the base case, women aged 25 to 49 years were
assumed to be screened every 3 years; women aged 50 to
64 years were screened every 5 years consistent with cur-
rent National Guidelines [22]. Differences in screening
coverage by age were modelled using estimates from the
Government Statistical Service (2003). Estimates for the
sensitivity and specificity of conventional cytology and
liquid cytology tests were based on published data [23,24]
and UK specific data [25], with separate estimates of sen-
sitivity used for CIN 1/CIN 2 and CIN 3. Fifty percent of
women were assumed to be screened with LBC and the
rest were assumed to be screened with conventional Pap
smears for the base case. Ten percent of women were esti-
mated to have inadequate Pap smear screening results and
were assumed to undergo repeat screening [26]. Women
with normal Pap smear results were assumed to return to
regular screening. Women with Atypical Squamous Cells
with Unknown Significance (ASCUS) or Low grade Squa-
mous Intraepithelial Lesion (LSIL) Pap smear results were
assumed to undergo repeat screening, with women
referred to colposcopy based on two repeat borderline
results. Women with ≥ High grade Squamous Intraepithe-
lial Lesion (HSIL) were assumed to be referred directly to
colposcopy. Colposcopy and biopsy were assumed to
have 90% sensitivity for detection of CIN [27]. Treatment
of CIN was assumed to be 100% effective. Twenty percent
of women with CIN 1 were assumed to be treated: this
proportion is consistent with the recommendation that
confirmed CIN 1 lesions are monitored via colposcopy
rather than treated [17]. The proportion of women treated
for CIN 2 and 3 was assumed to be 90% [17]. Screening
and treatment parameters are presented in Table 2.
Vaccination to prevent infection with HPV types 6, 11, 16
and 18 was assumed to be 98% effective, using the recent
results from the FUTURE II trial to determine efficacy of
the vaccine in preventing CIN 2–3 [6]. We conservatively
assumed the same efficacy for genital warts [5], but varied
this assumption widely in sensitivity analyses. The vaccine
was assumed to be administered to girls aged 12 years
through a school-based programme. To date, there is evi-
dence of a 5-year duration of vaccine efficacy [28]. We
assumed a lifetime duration of efficacy for the base case
consistent with a recently published analysis of the impact
of an HPV 16–18 vaccine on cervical cancer in the UK [29]
FIGO 3
Progression rates 0.9000 15 months
Probability of symptoms 0.7500 12 months
FIGO 4
Probability of symptoms 0.8000 12 months
Annual probability of survival after diagnosis, FIGO 1 Cancer Research UK 21
1 Year survival 0.977 12 months
2 Year survival 0.978 12 months
3 Year survival 0.963 12 months
4 Year survival 0.988 12 months
5 Year survival 0.988 12 months
Annual probability of survival after diagnosis, FIGO 2
1 Year survival 0.830 12 months
2 Year survival 0.835 12 months
3 Year survival 0.755 12 months
4 Year survival 0.870 12 months
5 Year survival 0.899 12 months
Annual probability of survival after diagnosis, FIGO 3
1 Year survival 0.590 12 months
2 Year survival 0.693 12 months
3 Year survival 0.778 12 months
4 Year survival 0.928 12 months
5 Year survival 0.963 12 months
Annual probability of survival after diagnosis, FIGO 4
1 Year survival 0.523 12 months
2 Year survival 0.782 12 months
3 Year survival 0.721 12 months
4 Year survival 0.925 12 months
5 Year survival 0.956 12 months
Table 1: Annual transition probabilities for the natural history model (Continued)Cost Effectiveness and Resource Allocation 2008, 6:4 http://www.resource-allocation.com/content/6/1/4
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as well as other analyses [30] but varied this assumption
widely in sensitivity analyses. Use of a booster, assumed
to be administered 10 years after the initial vaccine (i.e., at
age 22), to achieve a lifetime duration of efficacy was
examined in a sensitivity analysis [31]. Vaccine coverage
was 85% for the base case based on coverage rates
reported for the hepatitis B vaccine in the UK through a
school programme [32]. Since women can be infected
with multiple HPV types, and these other types can poten-
tially cause replacement CIN and cancer, we examined
this possibility in sensitivity analyses, assuming that 10
percent of women were coinfected with other high-risk
HPV types [33].
We modelled a reduction of approximately 35% for CIN
1, 55% for CIN 2 and 3 and 70% for cervical cancer (all
stages). This reflects the percentage of cervical cancer and
CIN 1–3 attributable to HPV types 6, 11, 16 and 18
[34,35]. Moreover, we assumed that 90% of warts were
attributable to infection with HPV types 6 and 11 [10]. We
Table 2: Screening, vaccine and cost parameters
Parameters Base case Ranges References
Screening characteristics
Screening interval 3 years in ages 25–49 years and 5 years 
in ages 50–64 years
NHS cervical screening programme 22
Coverage rates of target groups by 
age (2003)
25–29 74.0% NHS cervical screening programme 22
30–34 81.0%
35–39 83.7%
40–44 84.0%
45–49 83.8%
50–54 83.2%
55–59 81.4%
60–64 77.3%
Inadequate pap smear results 10% 5% – 20%
Pap Sensitivity for CIN 1/2 Pap 
sensitivity for CIN 1/2 (LBC)
61% 51% – 80% Nanda et al23and Karnon et al25
Pap Sensitivity for CIN 3 Pap 
Sensitivity for CIN 3 (LBC)
65% 65% – 90% Nanda et al23 and Karnon et al25
Pap Specificity for no CIN Pap 
Specificity for no CIN (LBC)
95.7% 90% – 99% Nanda et al25 and Kulasingam et al24
Colposcopy/Biopsy Sensitivity 90% 88% – 100% Mitchell et al27
Colposcopy/Biopsy Specificity 100% 65% – 100% Kulasingam et al24 and Karnon et al25
Vaccine characteristics
Vaccine efficacy for all 6, 11, 16, 18 
HPV types
98% 85% – 100% Villa et al5 and Future II 6
Duration of efficacy Lifetime From 10 years to lifetime Olsson et al 28 and Villa et al42
Vaccine coverage 85% 50%–90% Trotter et al31 and Bramley et al32
Booster coverage 50% Trotter et al31
Costs
Pap smear £23.7 £18 – £30 Brown et al 26
Curtis et al38
Colposcopy (with or without biopsy) £141.69 £113 – £170
Knife cone biopsy of cervix uteri £290.64 £232 – £349
CIN 1, CIN 2, CIN 3 £313.14 £250 – £376
FIGO I £12,142 £9,714 – £14,570 Curtis et al38 and Wolstenholme et 
al37
FIGO II £22,061 £17,649 – £26,473
FIGO III £21,785 £17,428 – £26,142
FIGO IV £23,402 £18,722 – £28,082
Genital warts £215.73 £172 – £259 Brown et al26 and Curtis et al38
Vaccine cost/dose £75 £70 – £80
Administration cost/dose £ 3.4 £0 – £12 Trotter et al31
Booster cost/dose £75
Administration cost for booster £10 Curtis et al38
Discount rates
Costs 3.5% 0 – 5%
Benefits 3.5% 0 – 5%Cost Effectiveness and Resource Allocation 2008, 6:4 http://www.resource-allocation.com/content/6/1/4
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modelled the impact of the vaccine as a direct reduction
in CIN rather than developing a type-specific model to
account for reductions in HPV type-specific infection, tak-
ing into account type-specific progression and regression
through the different CIN and cancer states similar to
Goldie et al. [36].
Costs for screening, diagnosis and treatment for cervical
cancer as well as for diagnosing and treating warts were
obtained from previously published studies [37,38] and
are presented in Table 2. The costs were inflated to 2005 £
using the Hospital and Community Services pay and
prices index [38]. While the NHS price of the vaccine is
£80.50, a volume-based discount will be applied for any
vaccination programme. For the purposes of this analysis,
we have assumed a cost per dose for the vaccine of £75
was used but varied from £70 to £80 in sensitivity analy-
ses. The cost for administration was assumed to be £3.40
per dose for the base case, but varied up to £12 in sensitiv-
ity analyses. Only direct costs were included in the analy-
ses, assuming a National Health System (NHS)
perspective.
Utilities for calculating quality-adjusted life expectancy
were based on ongoing studies and are summarized in
Table 3[39,40]. Time with disease was based on expert
opinion (Dr Barnabas, personal communication, 2005).
The utility value for those surviving cervical cancer was
assumed to be 1.0
Health outcomes and costs are discounted at 3.5% annu-
ally for the base case. Results are presented as average life-
time costs, average life-expectancy, life year saved (LYS),
Quality adjusted life year (QALY) and incremental cost-
effectiveness ratios (ICERs). Strategies that were more
costly and less effective, or less cost-effective than adjacent
strategies were considered "dominated."
Results
Validation of the model
The predicted age-specific annual incidence of invasive
cervical cancer in the UK population is similar to the
observed data in the UK (Figure 1). The model predicts a
lifetime risk of cancer in the absence of screening, for
women aged 20 to 79 years, of 2.0% and 0.71% with
screening, which are similar to estimates from a previ-
ously published modelling study that examined the
impact of changes in recommendations to the UK screen-
ing programme [17]. The distribution for FIGO stages pre-
dicted by the model is similar to data reported by Bjorge
et al. [20] (Stage I: 56%, Stage II: 29%, Stage III: 12%,
Stage IV: 3%).
Clinical outcomes
When vaccination is added to screening, under base case
assumptions, the lifetime risk of cancer is reduced from
0.71 to 0.29%. Considering a cohort of 100,000 women
in the UK, the model estimates that around 418 cervical
cancers, 127 deaths, 2,554 CIN 1, 1,683 CIN 2, 2,479 CIN
3 and 4,798 genital warts could be avoided (Table 4).
Economic outcomes
Compared to no screening or vaccination (natural his-
tory), screening only is associated with an ICER of
£11,156 per QALY. Compared to screening, vaccination
combined with screening had an incremental cost-effec-
tiveness ratio (ICER) of £21,059 per QALY and £34,687
per LYS (Figure 2 and Table 5).
As shown in Table 5, results were sensitive to the assump-
tion used for the duration of efficacy. If a 10 year duration
of vaccine efficacy is assumed, the ICER for screening and
vaccination compared to screening only would be
£68,417 per QALY (£116,743 per LY). If a booster was
needed to achieve lifetime protection, the ICER was
£26,782 per QALY (£44,114 per LY) under the assump-
tion that the booster was given at age 22 and coverage at
that age was 50%. Results were moderately sensitive to
time with an abnormality with ICERs for screening and
vaccination compared to screening only ranging from
£19,840 (for a 25% increase in the length of time with
abnormality) to £25,699 (for a 25% decrease in the length
of time) when screening, diagnosis and cancer were var-
ied. Results were very sensitive to the discount rate consid-
Table 3: Utility scores
Parameters Utility Time with Disease Ranges References
Screening Pap 0.98 1 months 2 weeks – 2 months Myers et al39 and Insinga et al40
ASCUS pap 0.94 1 month 2 weeks-2 months
>= LSIL pap 0.91 2 months 1–4 months
Warts 0.91 2 months 1–4 months
CIN 1 0.91 0.96 2 months 10 months 2–4 months 0–10 months
CIN 2–3 0.87 2 months 1–4 months
FIGO I 0.76 5 years 1–5 years
FIGO II 0.67 5 years 1–5 years
FIGO III 0.67 5 years 1–5 years
FIGO IV 0.67 5 years 1–5 yearsCost Effectiveness and Resource Allocation 2008, 6:4 http://www.resource-allocation.com/content/6/1/4
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ered for benefits: varying discount rates from 3,5% for
medical benefits (base case) to 1,5% would decrease the
ICER to £9,653 per QALY.
Varying the costs for screening, diagnosis and treatment
(Table 2) over a wide range, as well as varying the cost of
the vaccine between £70 and £80 had a moderate impact
on the cost-effectiveness of screening and vaccination
compared to screening only.
In multi-variable sensitivity analyses, we used a best and
worst case scenario to determine the possible bounds for
key aspects of the vaccine (duration, coverage and effi-
cacy). As shown, a combination of lower coverage, lower
efficacy and short duration has an important effect on the
ICER of vaccination and screening compared to screening
only.
Finally, as shown, the vaccine remains cost effective (with
QALYs as the outcome) if the age of screening can be
delayed or a less frequent screening interval used.
Discussion
These results suggest that adding vaccination to the cur-
rent screening programme in the UK, to prevent infection
with HPV types 6, 11, 16 and 18 is potentially cost-effec-
tive. The key parameters that affect this conclusion are the
duration of vaccine efficacy and whether a booster is
needed to achieve a duration that is sufficiently long to
provide protection during the years of peak HPV inci-
dence (modelled as a lifetime duration for this analysis).
Our findings are consistent with previous analyses per-
formed in the US that show that duration affects the cost-
effectiveness of screening and vaccination compared to
screening only [24,30]. However, in contrast to these anal-
Observed and predicted incidence of invasive cervical cancer in the UK Figure 1
Observed and predicted incidence of invasive cervical cancer in the UK. UK statistics. Cancer registration in England, 
2002.
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Table 4: Estimated cases of cervical cancer, cervical cancer deaths, cervical intraepithelial neoplasia grade 1 (CIN 1), grade 2 (CIN 2), 
grade 3 (CIN 3) and genital warts cases per 100 000 women who are screened, or vaccinated and screened over a lifetime
Cervical cancer 
cases
Deaths from 
cervical cancer
CIN 3 cases 
detected
CIN 2 cases 
detected
CIN 1 cases 
detected
Genital warts 
cases
Screening only 715 218 5325 3906 12453 7147
Screening and 
vaccination
297 91 2846 2223 9899 2349
Case avoided 418 127 2479 1683 2554 4798
* 85% vaccine coverage rate and lifetime duration of vaccine efficacyCost Effectiveness and Resource Allocation 2008, 6:4 http://www.resource-allocation.com/content/6/1/4
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yses, our results suggest that a vaccination programme
added to screening in the UK would be cost-effective with-
out the need to change screening interval and/or the age
of first screen. In the UK, screening is started at a later age,
and a less frequent screening interval is used, compared to
the US. The current UK strategy thus avoids the increased
costs associated with detecting HPV-related changes, espe-
cially in younger women, that are more likely to regress.
To date, all cost-effectiveness analyses of HPV vaccination
show that duration of efficacy will be a key to determining
how cost-effective the vaccine will be. The need for a long
duration of vaccine efficacy is consistent with our under-
standing of the natural history of HPV infection: progres-
sion to cervical cancer can take more than 10 years [41].
Currently, there is approximately 5 years of data of vaccine
duration [42]. Long term monitoring of women currently
participating in the vaccine trial will be needed to deter-
mine if and when a booster should be given. If a booster
is needed our analyses show that the coverage achieved
with a booster will affect the overall cost-effectiveness of
vaccination and screening compared to screening only.
One possible solution for increasing booster coverage
beyond the 50% we modelled is if vaccination could be
administered during the cervical cancer screening visit.
We did not use a quadrivalent type-specific model for this
analysis. There is a need for population-based data that
accounts for the distribution of these specific types within
CIN from the UK. In addition, data on the impact of the
vaccine on the overall reduction in CIN (as opposed to the
type-specific reduction in CIN reported to date) due to
these specific types, in previously unexposed girls, is also
needed, to confirm the pooled estimates reported in the
literature. Work is currently underway to refine existing
models, including the one used here, to more accurately
reflect the expected type-specific reduction in CIN and
cancer when girls are vaccinated using data from the UK
(Dr R. Barnabas, personal communication, 2007).
The use of QALYs is important since it allows us to incor-
porate, among other things, feelings of anxiety and
embarrassment due to abnormal Pap test results as well as
genital warts. However, the utilities used were derived
from a study conducted among college-aged students in
the US [39]. Although utilities derived from a UK popula-
tion as well as a study of time spent in a given health state
would more accurately reflect the morbidity associated
with cancer, CIN and warts, this information has yet to be
published. Results from the sensitivity analysis show that
duration of symptoms has only a modest influence on the
results.
Our model is conservative in that it does not take into
account the impact of the vaccine on herd immunity.
Prior analyses in the US with transmission models that
accounted for herd immunity effects [43,44] suggest that
the ICER for vaccination and screening compared to
screening only would be much more attractive, even if the
vaccine was only given to girls. In future analyses, we will
also need to determine whether vaccinating boys in addi-
tion to girls will be cost-effective, taking into account the
potential benefit of the HPV 6 and 11 component of the
vaccine in preventing genital warts in men.
Although the vaccine has recently been approved for use
in the UK, its use is not mandatory [4]. In addition, there
has been no decision made on the choice of vaccine (Cer-
varix or Gardasil). As such, patients and payers will have
to decide whether the cost of the vaccine represents value
for money. To the extent that one vaccine has a higher cost
than the other, and is not covered by a national program,
vaccine coverage will differ from what we have modeled.
Our analyses suggest that although there has not been a
move to change screening to offset the costs of adding a
vaccination program, one potential benefit of the vaccine
that may make it more attractive for both patients and
payers, is if eventually, a successful vaccination program
allows women to be screened less frequently. As shown,
depending on the characteristics of the vaccine, the age
and/or frequency of screening may be delayed and still be
cost-effective.
Other limitations include lack of a probabilistic sensitivity
analysis and the fact that the model provides a conserva-
tive estimate of the true value of a quadrivalent HPV vac-
cine targeted at HPV types 6, 11, 16 and 18, in terms of
health benefits as it does not take into consideration the
potential reduction of adenocarcinoma, vulvar and vagi-
nal intraepithelial neoplasia, vulval and vaginal cancers,
as well as laryngeal papillomatosis associated with the
Efficiency curve comparing a strategy of screening only to a  strategy of vaccination plus screening Figure 2
Efficiency curve comparing a strategy of screening 
only to a strategy of vaccination plus screening.
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vaccine HPV types [45]. In terms of the latter, the benefits
of a quadrivalent vaccine are to some extent underesti-
mated in this analysis. In terms of the former, although
one study to date has conducted a probabilistic sensitivity
analysis to determine credible intervals for the natural his-
tory component of the model [46], there is a lack of infor-
mation to determine the appropriate distributions for use
in models this complex. As such, this analysis used trian-
gular distributions, although these have well known limi-
tations. This highlights the need for epidemiologic studies
to include information on the distributions as well as
point estimates and confidence intervals.
Conclusion
In conclusion, our results suggest that adding a quadriva-
lent vaccine to the current screening programme in the UK
is potentially cost-effective. In order to more accurately
quantify the effect that the vaccine will have, future mod-
els will need to account for the actual reduction in CIN
and cancer based on data from the vaccine trials con-
ducted in the UK, as well as to incorporate herd immunity
effects.
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Table 5: One-way sensitivity analyses comparing cervical cancer screening only and cervical cancer screening associated with a 
quadrivalent HPV vaccination programme
Parameters ICER (£/QALYs) ICER (£/LYs)
Base case 21,059 34,687
Vaccine duration
10 years 68,417 116,743
10 years + booster to achieve lifetime protection 26,782 44,114
20 years 30,777 52,578
Multiple infections
15% 24,085 39,842
Vaccine efficacy
85% 25,081 40,831
Vaccine coverage
50% 21,581 34,426
Screening coverage rate
-50% 16,266. 35,476
-10% 19,926 34,681
Screening, diagnosis and treatment costs
-20% 21,717 35,771
+20% 20,401 33,602
Vaccine costs
70 £ 19,450 32,036
80 £ 22,668 37,337
Utilities
25% decrease for screening utilities; 1-year duration for time with cancer 25,600
25% increase in time with disease; 5-year duration for time with cancer 19,840
Cancer utilities only (5 year duration) 27,954
Discount rates
0% costs; 0% medical benefit 3,123 4,122
3% costs; 3% medical benefit 17,089 27,066
3,5% costs; 1,5% medical benefit 9,653 13,797
5% costs; 5% medical benefit 36,618 68,760
Multivariate Sensitivity Analyses
10 years duration, 50% coverage, 85% efficacy 84,925 140,705
Lifetime duration, 90% coverage, 100% efficacy 20,316 33,752
Changes to Screening (assuming base case assumptions for the vaccine)
Screening every 5 years starting at age 25 13,449 36,712
Screening starting at age 26 20,724 34,441
Screening starting at age 28 16,527 34,153
Screening starting at age 30 13,680 34,989
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